Business Description
Monte Rosa Therapeutics Inc
NAICS : 541714
SIC : 2834
Description
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.85 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.25 | |||||
| Debt-to-EBITDA | -0.34 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -49.5 | |||||
| 3-Year EPS without NRI Growth Rate | -49.2 | |||||
| 3-Year FCF Growth Rate | -48.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.99 | |||||
| 9-Day RSI | 39.4 | |||||
| 14-Day RSI | 40.1 | |||||
| 6-1 Month Momentum % | -55.16 | |||||
| 12-1 Month Momentum % | -67.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.09 | |||||
| Quick Ratio | 8.09 | |||||
| Cash Ratio | 7.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -64.2 | |||||
| Shareholder Yield % | -5.36 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -55.16 | |||||
| ROA % | -43.15 | |||||
| ROIC % | -182.77 | |||||
| ROC (Joel Greenblatt) % | -224.62 | |||||
| ROCE % | -49.27 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.8 | |||||
| Price-to-Tangible-Book | 0.8 | |||||
| EV-to-EBIT | -0.12 | |||||
| EV-to-Forward-EBIT | -0.11 | |||||
| EV-to-EBITDA | -0.12 | |||||
| EV-to-Forward-EBITDA | -0.11 | |||||
| EV-to-FCF | -0.14 | |||||
| Price-to-Net-Current-Asset-Value | 1.29 | |||||
| Price-to-Net-Cash | 1.33 | |||||
| Earnings Yield (Greenblatt) % | -833.33 | |||||
| FCF Yield % | -82.31 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GLUE
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Monte Rosa Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.69 | ||
| Beta | 0 | ||
| Volatility % | 94.5 | ||
| 14-Day RSI | 40.1 | ||
| 14-Day ATR ($) | 0.312659 | ||
| 20-Day SMA ($) | 3.29075 | ||
| 12-1 Month Momentum % | -67.41 | ||
| 52-Week Range ($) | 2.44 - 9.83 | ||
| Shares Outstanding (Mil) | 50.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Monte Rosa Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Monte Rosa Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Monte Rosa Therapeutics Inc Frequently Asked Questions
What is Monte Rosa Therapeutics Inc(GLUE)'s stock price today?
The current price of GLUE is $2.96. The 52 week high of GLUE is $9.83 and 52 week low is $2.44.
When is next earnings date of Monte Rosa Therapeutics Inc(GLUE)?
The next earnings date of Monte Rosa Therapeutics Inc(GLUE) is 2024-02-09 Est..
Does Monte Rosa Therapeutics Inc(GLUE) pay dividends? If so, how much?
Monte Rosa Therapeutics Inc(GLUE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers